Results from the randomised controlled study of 12,209 people at high risk of developing cancer, Early detection of Cancer of the Lung Scotland, were presented TODAY at the International Association for the Study of Lung Cancer's (IASLC) 2019 World Conference on Lung Cancer in Barcelona.
In June, Biodesix announced acquisition of Oncimmune and the EarlyCDT Lung test in the United States.
Prof. Frank Sullivan, Professor of Primary Care Medicine at the University of St. Andrews and chief investigator for the ECLS trial, noted the global significance of a blood test, followed by CT scans, to increase the number of patients diagnosed at an earlier stage of disease, when surgery is still possible and prospects for survival are higher.
This early diagnosis is especially important in the case of lung cancer because approximately 85 % of patients are diagnosed with the disease at a late stage, when the cancer has spread to other parts of the body and the chances of survival are low.
In addition to its potential in lung cancer screening, the EarlyCDT Lung test also helps physicians to determine if a pulmonary nodule is potentially cancerous, helping physicians manage nodule patients.
The Biodesix Nodify XL2 test, is used to help physicians rule-out malignancy in low-to-moderate risk incidental lung nodules. Biodesix will offer complementary tests that help empower physicians to stratify patients into distinct nodule management pathways.
Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer.
The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence.
Biodesix said it is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies.
The Biodesix Lung Reflex strategy integrates the GeneStrat and VeriStrat tests to support treatment decisions with results in 72 hours.
The Nodify XL2 nodule test evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval